MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress

MaaT Pharma announced positive results from its Early Access Program (EAP) for Xervyteg® in treating acute Graft-versus-Host Disease (aGvHD) at the European Hematology Association Congress 2025. An oral presentation outlined data from 173 patients treated under EAP, reflecting strong efficacy. This data supports findings from the ARES trial and is part of the EMA Marketing Authorization Application submitted this June.

Xervyteg® demonstrated a significant safety profile with a Gastrointestinal Overall Response Rate of 53% at 28 days, noting Complete Response in 30% of patients. The overall patient survival rate was 55% at 6 months, highlighting the therapy's potential in contexts of high unmet medical need.

A subset of patients showing resistance to previous treatments further confirmed the drug's efficacy, with survival extending notably among responders. This data reinforces Xervyteg®'s potential for durable efficacy and favorable safety in severe aGvHD cases.